Anti-CD40L mAb treatment prevents the onset of a memory T-cell response. At day 0, 3 groups of C57BL/6 mice were given injections with PBS (n = 5), 106 BALB/c BMCs (n = 5), or 106 BALB/c BMCs in combination with anti-CD40L mAb (n = 5). At day 28, an in vivo cytotoxicity assay was performed and peripheral-blood samples were collected 3 hours and 3 days later. The C57BL/6 mice initially treated with PBS eliminated 32.3% ± 4.0% of the CFSE-labeled BALB/c splenocytes within 3 hours (A) and 96.4% ± 1.4% within 3 days after infusion (D). The C57BL/6 mice initially treated with 106 BALB/c BMCs eliminated 96.8% ± 3.2% of the CFSE-labeled BALB/c splenocytes within 3 hours after infusion (B), and the C57BL/6 mice initially treated with anti-CD40L mAb and 106 BALB/c BMCs eliminated 25.6% ± 3.7% of the CFSE-labeled BALB/c splenocytes within 3 hours (C) and 96.9% ± 1.5% within 3 days after infusion (E). At day 56, 4 weeks after the first in vivo cytotoxicity assay, a second in vivo cytotoxicity assay was performed. The C57BL/6 mice initially treated with PBS eliminated 99.2% ± 0.6% of the CFSE-labeled BALB/c splenocytes within 3 hours after infusion (F). The C57BL/6 mice initially treated with anti-CD40L mAb and 106 BALB/c BMCs eliminated 39.1% ± 5.5% of the CFSE-labeled BALB/c splenocytes within 3 hours (G). For each group a representative dot plot is displayed.
